Compare NFE & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | SGHT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 309.6M |
| IPO Year | 2018 | 2021 |
| Metric | NFE | SGHT |
|---|---|---|
| Price | $0.38 | $5.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.50 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 5.3M | 186.8K |
| Earning Date | 04-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | $77,363,000.00 |
| Revenue This Year | $110.34 | $11.67 |
| Revenue Next Year | $3.54 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $3.11 |
| 52 Week High | $4.96 | $9.24 |
| Indicator | NFE | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 59.01 |
| Support Level | $0.32 | $4.76 |
| Resistance Level | $0.54 | $5.66 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 27.61 | 60.78 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.